Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Recher

Showing results (451-460 of 488) with videos related to

Pageof 49
Sort By:
Journal of Virology|February 13, 2015
Deficiency of the B cell-activating factor receptor results in limited CD169+ macrophage function during viral infectionHaifeng C Xu, Jun Huang, Vishal Khairnar, et al.
NEJM Evidence|April 28, 2026
Clonal Dynamics of Hematopoiesis in Aplastic Anemia after Immunosuppression and EltrombopagDeniz Ece Kaya, Riley Cook, Simona Iacobelli, et al.
Journal of Clinical Immunology|August 22, 2017
Detection of Sp110 by Flow Cytometry and Application to Screening Patients for Veno-occlusive Disease with ImmunodeficiencyFlorian A Marquardsen, Fabian Baldin, Florian Wunderer, et al.
Blood Advances|October 25, 2024
Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OSThomas Cluzeau, Fabio Guolo, Edmond Chiche, et al.
British Journal of Haematology|April 19, 2022
A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutationsLionel Adès, Nicolas Duployez, Agnes Guerci-Bresler, et al.
Blood|April 20, 2022
Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO studyNicolas Duployez, Laëtitia Largeaud, Matthieu Duchmann, et al.
American Journal of Hematology|December 31, 2013
Azacitidine in untreated acute myeloid leukemia: a report on 149 patientsSylvain Thépot, Raphael Itzykson, Valerie Seegers, et al.
Nature Communications|February 19, 2015
CEACAM1 induces B-cell survival and is essential for protective antiviral antibody productionVishal Khairnar, Vikas Duhan, Sathish Kumar Maney, et al.
Nature Immunology|March 25, 2022
Author Correction: DOCK8 functions as an adaptor that links TLR-MyD88 signaling to B cell activationHaifa H Jabara, Douglas R McDonald, Erin Janssen, et al.
Nature Immunology|May 15, 2012
DOCK8 functions as an adaptor that links TLR-MyD88 signaling to B cell activationHaifa H Jabara, Douglas R McDonald, Erin Janssen, et al.
Pageof 49

Showing results (451-460 of 488) with videos related to

Sort By:
Pageof 49
Journal of Virology|February 13, 2015
Deficiency of the B cell-activating factor receptor results in limited CD169+ macrophage function during viral infectionHaifeng C Xu, Jun Huang, Vishal Khairnar, et al.
NEJM Evidence|April 28, 2026
Clonal Dynamics of Hematopoiesis in Aplastic Anemia after Immunosuppression and EltrombopagDeniz Ece Kaya, Riley Cook, Simona Iacobelli, et al.
Journal of Clinical Immunology|August 22, 2017
Detection of Sp110 by Flow Cytometry and Application to Screening Patients for Veno-occlusive Disease with ImmunodeficiencyFlorian A Marquardsen, Fabian Baldin, Florian Wunderer, et al.
Blood Advances|October 25, 2024
Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OSThomas Cluzeau, Fabio Guolo, Edmond Chiche, et al.
British Journal of Haematology|April 19, 2022
A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutationsLionel Adès, Nicolas Duployez, Agnes Guerci-Bresler, et al.
Blood|April 20, 2022
Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO studyNicolas Duployez, Laëtitia Largeaud, Matthieu Duchmann, et al.
American Journal of Hematology|December 31, 2013
Azacitidine in untreated acute myeloid leukemia: a report on 149 patientsSylvain Thépot, Raphael Itzykson, Valerie Seegers, et al.
Nature Communications|February 19, 2015
CEACAM1 induces B-cell survival and is essential for protective antiviral antibody productionVishal Khairnar, Vikas Duhan, Sathish Kumar Maney, et al.
Nature Immunology|March 25, 2022
Author Correction: DOCK8 functions as an adaptor that links TLR-MyD88 signaling to B cell activationHaifa H Jabara, Douglas R McDonald, Erin Janssen, et al.
Nature Immunology|May 15, 2012
DOCK8 functions as an adaptor that links TLR-MyD88 signaling to B cell activationHaifa H Jabara, Douglas R McDonald, Erin Janssen, et al.
Pageof 49